Fieldpoint Private Securities LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 285.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,715 shares of the company’s stock after purchasing an additional 5,715 shares during the period. Fieldpoint Private Securities LLC’s holdings in Novo Nordisk A/S were worth $371,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Proficio Capital Partners LLC grew its position in Novo Nordisk A/S by 6.1% during the 2nd quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company’s stock worth $111,000 after purchasing an additional 150 shares in the last quarter. AlphaMark Advisors LLC grew its position in Novo Nordisk A/S by 1.1% during the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after purchasing an additional 30 shares in the last quarter. Zions Bancorporation grew its position in Novo Nordisk A/S by 677.1% during the 3rd quarter. Zions Bancorporation now owns 2,852 shares of the company’s stock worth $137,000 after purchasing an additional 2,485 shares in the last quarter. MUFG Americas Holdings Corp grew its position in Novo Nordisk A/S by 100.0% during the 2nd quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock worth $129,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Parallel Advisors LLC grew its position in Novo Nordisk A/S by 44.4% during the 2nd quarter. Parallel Advisors LLC now owns 4,108 shares of the company’s stock worth $174,000 after purchasing an additional 1,264 shares in the last quarter. Hedge funds and other institutional investors own 6.18% of the company’s stock.

Novo Nordisk A/S (NYSE:NVO) traded up $0.07 during trading on Thursday, hitting $53.39. 2,070,300 shares of the stock traded hands, compared to its average volume of 2,081,110. Novo Nordisk A/S has a fifty-two week low of $32.83 and a fifty-two week high of $53.48. The stock has a market cap of $135,966.00, a PE ratio of 23.28, a P/E/G ratio of 3.14 and a beta of 0.63.

In related news, insider Eric S. Sprott purchased 50,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $8.34 per share, for a total transaction of $417,000.00. Insiders own 0.07% of the company’s stock.

Several research firms have weighed in on NVO. Bank of America upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, December 6th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a report on Friday, December 1st. Zacks Investment Research cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Friday, October 27th. Finally, BNP Paribas cut shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $55.00.

ILLEGAL ACTIVITY WARNING: “Novo Nordisk A/S (NVO) Shares Bought by Fieldpoint Private Securities LLC” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dailypolitical.com/2017/12/14/novo-nordisk-as-nvo-shares-bought-by-fieldpoint-private-securities-llc.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.